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Summary We investigated the reconstitutive potential of haematopoietic progenitor cells collected in autologous whole blood during
multicycle dose-intensified chemotherapy. Forty patients with metastatic solid tumours were treated with up to six cycles of cisplatin and
escalating doses of ifosfamide every 14 days. Cisplatin was administered in 3% sodium chloride over 3 h, followed by ifosfamide over 24 h
and mesna over 36 h. The first cohort of patients received granulocyte colony-stimulating factor (G-CSF) days 4-14. Once dose-limiting
toxicity was reached in cohort 1, the study continued with a second cohort of patients, in whom, in addition to G-CSF on days 4-14, 500 ml of
G-CSF and chemotherapy-primed' whole blood was collected on day 15, i.e. on day 1 of treatment cycles two to six, before cisplatin
administration. This volume of blood was kept unprocessed at 40C and reinfused 20-24 h after the completion of ifosfamide. In cohort 1,
dose-limiting toxicity (DLT) was reached at ifosfamide 6.0 g m-2 with two out of six of the patients developing neutropenic fever. Although in
cohort 2 no neutropenic fever was encountered, neither the frequency nor the duration of grade 4 neutropenia and thrombocytopenia were
reduced. Cumulative asthenia resulted in DLT at 7.0 g m-2. The median number of CD34+ cells in 500 ml of whole blood after the first cycle
(i.e. at start of cycle 2) was 1.15 x 106 kg-1. This number was significantly greater after the second cycle (2.06 x 106 kg-', P = 0.01) and then
gradually decreased after cycles three to six. After storing whole blood, the number of CD34 + cells had not decreased (median + 10%). We
conclude that the method of combined bone marrow support by G-CSF and haematopoietic progenitor cells in autologous whole blood
collected before each cycle of a 2-weekly regimen of cisplatin-ifosfamide does not result in clinically measurable reduced bone marrow
toxicity compared with what can be expected by the use of G-CSF alone.
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The availability of peripheral blood haematopoietic progenitor
cells (PBPCs) from different harvesting techniques and the possi-
bilities of storage have raised interest in the administration of
repetitive, closely spaced cycles of dose-intensive chemotherapy,
each with PBPC rescue (Benjamin et al, 1995; Leyvraz et al, 1995;
Pettengell et al, 1995; Vahdat et al, 1995; Rodenhuis et al, 1996). It
was previously reported that autologous whole blood (without
processing through a cell separator) 'primed' with chemotherapy
and granulocyte colony-stimulating factor (G-CSF) provided
sufficient PBPCs for myelosupportive effects (Pettengell et al,
1994, 1995; Preti et al, 1994; Ossenkoppele et al, 1996). In addi-
tion, PBPCs can be stored at 4°C for 48-72 h (Ossenkoppele et al,
1994, 1996; Pettengell et al, 1994; Preti et al, 1994). PBPCs can
thus be harvested, kept unfrozen and reinfused after the adminis-
tration of chemotherapy. We recently reported on a 2-weekly
regimen of cisplatin-ifosfamide with G-CSF support (Planting
et al, 1996). In that study, haematological toxicity prevented the
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timely administration of the chemotherapy. In the present study,
we investigated the feasibility and usefulness of PBPCs collected
in G-CSF and chemotherapy-'primed' whole blood, by assessing
the myelosupportive effects of G-CSF support alone, and G-CSF
plus the reinfusion of PBPCs collected in 500 ml of autologous
whole blood during each cycle of a modified 2-weekly regimen of
cisplatin-ifosfamide chemotherapy.
PATIENTS AND METHODS
Eligibility required the histological proof of solid tumour for
which cisplatin and ifosfamide were considered to be active
agents, age < 70 years, WHO performance status 0-2, no previous
chemotherapy, normal peripheral blood counts, creatinine
clearance . 60 ml min-', serum bilirubin < 25 ,umol 1-', serum
albumin 2 25 g 1- and written informed consent.
The chemotherapy consisted ofcisplatin at a dose of70 mg m-2
and escalating doses of ifosfamide starting at 5 g m-2 with 0.5-g
dose increments per dose level. Prehydration consisted of 11 of
dextrose/saline + 20 mmol potassium chloride and 2 g of magne-
sium sulphate. Cisplatin, dissolved in 250 ml ofhypertonic saline
(3% sodium chloride), was administered over 3 h, followed by
ifosfamide plus mesna at two-thirds of the dose of ifosfamide in
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Table 1 Haematological toxicity per patient in cohort 1
CTC grades
Dose No. of No. of WBC Granulocytes Platelets
(g m-2) patients cycles
1 2 3 4 1 2 3 4 1 2 3 4
5.0 3 NA 0 0 0 2 0 0 0 2 0 1 2 0
5.5 6 NA 0 0 1 4 0 0 0 5 1 0 3 2
6.0 9 NA 0 0 5 4 0 2 2 5 2 3 1 3
18
5.0 NA 11 0 0 1 3 1 0 1 2 3 2 3 0
5.5 NA 29 2 6 6 5 2 4 2 9 9 4 6 2
6.0 NA 35 6 1 13 8 0 5 9 9 11 7 3 3
75
NA, not applicable. CTC, common toxicity criteria.
Table 2 Haematological toxicity per patient in cohort 2
CTC grades
Dose No. of No. of WBC Granulocytes Platelets
(g m-2) patients cycles
1 2 3 4 1 2 3 4 1 2 3 4
5.5 6 NA 0 0 2 2 0 0 0 4 1 0 0 4
6.0 11 NA 0 0 3 7 0 1 0 9 2 3 4 2
6.5 6 NA 0 0 1 4 0 0 0 5 0 2 1 2
7.0 6 NA 0 0 1 5 0 0 0 6 0 1 1 4
29
5.5 NA 20 1 0 6 5 0 1 1 9 4 0 6 5
6.0 NA 32 1 5 8 12 1 6 2 16 11 6 9 3
6.5 NA 22 0 2 5 9 1 2 5 8 4 4 3 3
7.0 NA 19 0 1 4 14 0 2 3 14 5 5 5 4
93
NA, not applicable. CTC, common toxicity criteria.
4 1 of dextrose/saline + 60 mmol potassium chloride and 8 g of
magnesium sulphate over 24 h. The remaining one-third of the
dose of mesna was administered in another 2 1 dextrose/saline
during the next 12 h. A maximum of six cycles per patient was
planned. Subsequent cycles of chemotherapy were given if WBC
. 2.0 x 109 1- and platelets . 60 x 109 1-1. The protocol did not
allow dose reductions. Three to six patients were to be entered at
each dose level. Dose-limiting toxicity (DLT) was defined as
grade 4 neutropenia > 5 days or with fever > 38°C over a 12-h
period or > 38.5°C once, or grade 4 thrombocytopenia with
bleeding, or . grade 3 non-haematological toxicity occurring in
. one ofthree or 2 two ofsix patients per dose level. Blood counts
were measured thrice weekly. All cycles of treatment per patient
were taken into account for defining DLT.
The firstcohort ofpatients (cohort 1, G-CSF alone) received r-met
Hu G-CSF (Filgrastim, Amgen, Breda, The Netherlands) subcuta-
neously at a dose of 5 ,ug kg-' once daily days 4-9, twice daily days
10-13 and a last dose in the morning of day 14. The higher daily
dose of G-CSF on days 10-14 was based on its greater ability to
stimulate endogenous marrow progenitor cells (Dreger et al, 1994).
Once DLT was reached in cohort 1, the study continued with a
second cohort (cohort 2), treated at the same dose levels as those
of cohort 1 with the exception of the first dose level, with the
intention to try and achieve a higher DLT. In cohort 2, in addition
to G-CSF, 500 ml ofautologous G-CSF 'primed' whole blood was
collected by venesection on day 15, at the time of neutrophil
recovery and maximum release ofprogenitor cells (Benjamin et al,
1995; Planting et al, 1996) i.e. day 1 ofcycle two to six, before the
administration of cisplatin. The blood was collected in CPD/
SAG-M (Biopack-compoflex NPB Emmer Compascum, The
Netherlands) and cooled rapidly to 4°C in a refrigerator at the
blood bank and kept at 40C without further processing. The blood
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Table 3 Non-haematological toxicity and reasons for withdrawal
Dose level Number of Nausea/ Infectiona Asthenia Renal Tumour
patients vomiting toxicityb progression
Cohort 1 5.0 3 - 1 - - 1
5.5 6 2 - - - 1
6.0 9 1 1 1 1 3
Cohort 2 5.5 6 1 - - 1 1
6.0 11 1 - 2 2 2
6.5 6 1 - - 1 -
7.0 6 3 - 2 - -
alnfection without concomitant severe neutropenia. bCreatinine clearance decreased to < 45 ml min
was reinfused 20-24 h after the completion of the ifosfamide
infusion (51-55 h after collection).
CD34+ cells were measured by flow cytometry using the
CD34/FITC (anti-HPCA-2) MAb, Becton Dickinson Immuno-
cytometry Systems (BDIS), San Jose, CA, USA (Gratema et al,
1997), immediately after collection and at the time ofreinfusion.
RESULTS
A total of 40 patients, median age 55 years (range 19-70 years)
were treated. Of these, 15 had gastric adenocarcinoma, nine had
poorly differentiated cancer of unknown primary site, five had
malignant melanoma, and nine had miscellaneous metastatic solid
tumours. Pretreatment characteristics including median age, sex,
WHO performance status, peripheral blood cell counts at entry and
distribution of tumour types were essentially identical for the two
patient cohorts (data not shown).
In cohort 1, 15 patients received 67 cycles at ifosfamide doses of
5.0, 5.5 and 6.0 g m-2. Haematological toxicity is listed in Table 1.
Dose-limiting toxicity (DLT) was reached at 6.0 g m-2, with two
out of six patients developing neutropenic fever.
Subsequently, in cohort 2, 25 patients received 87 cycles with
ifosfamide at 5.5, 6.0, 6.5 and 7.0 g m-2. Haematological toxicity is
given in Table 2. Although no neutropenic fever was encountered,
neither the frequency nor the duration (median 3 days in both
cohorts) of grade 4 neutropenia and thrombocytopenia was
reduced in comparison with cohort 1. Non-haematological toxici-
ties and reasons for withdrawal are given in Table 3. Cumulative
asthenia resulted in DLT in cohort 2 at 7.0 g m-2.
As non-haematological toxicity was dose limiting in cohort 2, in
order to make a better comparison between myelotoxicity encoun-
tered in cohort 1 and cohort 2, three additional patients at the ifos-
famide dose of 6.0 g m-2 were entered in both cohorts. All cycles
of treatment per patient were taken into account for defining DLT,
but for each patient who did not complete a minimum of three
cycles, an additional patient was entered. This resulted in a total of
nine patients and 35 cycles at dose level 6.0 g m-2 in cohort 1, and
11 patients and 32 cycles at dose level 6.0 g m-2. The data for these
patients have been included in Tables 1-3.
Figure 1 shows the median number ofCD34+ cells in 500 ml of
whole blood harvested at the time ofcycles two to six. The median
number of CD34+ cells in 500 ml of whole blood after the first
cycle (i.e. at start ofcycle 2) was 1.15 x lP kg-I body weight. This
number was significantly greater after the second cycle (2.06 x 106
kg-', P=0.01) and then gradually decreased after cycles three to
six. Although there was a wide range in the percentual difference
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Figure 1 Numbers of CD34 cells x 106 kg-' body weight in 500 ml of whole
blood harvested at cycles two to six
in numbers ofCD34+ cells after 51-55 h storage at 40C of - 118%
to +41% (2.5-97.5 percentile), there was no median decrease (in
fact, there was a small increase) in the number of CD34+ cells of
+10.9%. (The small median increase during storage might be
explained by further maturation of progenitor cells with initially
low levels ofCD34+ expression).
DISCUSSION
There is a rationale for delivering dose-intensified chemotherapy
during repetitive cycles (Gurney et al, 1993). With the technical
ability to increase the numbers of PBPCs in peripheral blood with
G-CSF and chemotherapy, the approach of multiple cycles of
dose-intensive chemotherapy each to be followed by progenitor
cell reinfusion has become possible. For this purpose two different
methods are being investigated. One technique is the harvest of
progenitor cells by large-volume apheresis after conventionally
dosed chemotherapy and cryopreserving the harvest in separate
amounts, enabling progenitor cell support after each ofsubsequent
dose-intensive cycles of chemotherapy (Benjamin et al, 1995;
Leyvraz et al, 1995; Vahdat et al, 1995; Rodenhuis et al, 1996).
The second approach is the use of progenitor cells collected
before each cycle of chemotherapy, which are kept refrigerated
until the chemotherapy has been administered and cells can be
reinfused. In addition, there is evidence that sufficient numbers of
progenitor cells can be harvested in relatively small amounts of
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whole blood (Ossenkoppele et al, 1994, 1996; Pettengell et al,
1994, 1995). This approach would appear simple and cost-effective
as it does neither require apheresis equipment nor cryopreservation
of the cells. Furthermore, there is evidence of similar or even
greater viability and colony-forming potential of short-term refrig-
erated cells compared with cryopreserved cells (Preti et al, 1994).
We studied the latter approach using progenitor cells present in
a collection of G-CSF and 500 ml of chemotherapy-'primed'
autologous whole blood in a 2-weekly dose-intensified cisplatin-
ifosfamide regimen. Although we were able to harvest significant
numbers of CD34+ cells, especially during the initial cycles of
chemotherapy, the reinfusion of these cells did not translate into a
measurable reduction of the myelotoxic effects by the chemo-
therapy. It could be argued, however, that despite the increased
dose of ifosfamide by 30% in cohort 2, the myelotoxicity with
whole blood PBPCs at these dose levels of 6.5 and 7.0 g m-2 was
very similar to that at the lower dose levels without PBPCs. Also
no neutropenic fever was encountered in cohort 2.
Nonetheless, the reconstitutive potential of PBPCs in whole
blood in this schedule appears limited. The explanation for this
cannot be found in technical aspects, as the harvesting technique,
the medium and the duration of storage at 4°C were the same as
applied by two investigators who reported on the use of PBPCs in
whole blood (Ossenkoppele et al, 1994, 1996; Pettengell et al,
1995). The same holds true for the number of progenitor cells
collected and the percentage of viable cells remaining after
storage. Although the numbers ofCD34+ cells collected in 500 ml
of blood in this study were slightly less than reported in the
other studies in 500-750 ml of whole blood, the median number
of CD34+ cells of 1.15 x 106 kg-' at the second cycle and
2.06 x 106 kg-' at the third cycle should enable better identifiable
effects on the haemopoietic reconstitution during the course of
treatment. Also, the time interval of20-24 h between the comple-
tion of ifosfamide infusion and reinfusion ofPBPCs appears to be
a sufficient wash-out period.
We have recently reported that the administration of G-CSF
within 48 h before the start of chemotherapy has a detrimental
effect on the bone marrow toxicity (de Wit et al, 1996). As, for
successful PBPC collection, G-CSF needs to be continued until
the time of collection, so as to keep the stem cells in the circula-
tion, this finding is a clear disadvantage ofthe method ofadminis-
tering chemotherapy immediately after the harvest of PBPCs. In
the present study, the last dose of G-CSF was administered
approximately 24 h before the start of chemotherapy, thereby
possibly resulting in harmful effects on the bone marrow.
However, the continued administration of G-CSF in our study
cannot be an explanation for the different findings by Pettengell et
al (1995) and Ossenkoppele et al (1994, 1996), as in their studies
G-CSF was also continued until or even within 24 h before the
administration ofchemotherapy (personal communication).
The alternative method of harvesting PBPCs by apheresis after
one or two cycles of conventionally dosed chemotherapy and
cryopreserving the cells in separate quantities for subsequent
support of several of dose-intensive chemotherapy cycles appears
a more attractive approach. We and others have demonstrated in
patients with breast cancer and germ cell cancer that sufficient
numbers of PBPCs can be collected by single apheresis to support
three or four dose-intensive chemotherapy cycles (Bokemeyer et
al, 1996; Rodenhuis et al, 1996).
We conclude that the method ofcombined bone marrow support
by G-CSF and PBPCs in autologous whole blood collected before
each cycle of a 2-weekly cisplatin-ifosfamide regimen does not
result in clinically measurable reduced bone marrow toxicity,
compared with what can be expected of support by G-CSF alone.
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